CL2015001608A1 - Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. - Google Patents

Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Info

Publication number
CL2015001608A1
CL2015001608A1 CL2015001608A CL2015001608A CL2015001608A1 CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1 CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1
Authority
CL
Chile
Prior art keywords
formulation
humanized anti
proliferative disorder
antibody solution
treat autoimmune
Prior art date
Application number
CL2015001608A
Other languages
English (en)
Spanish (es)
Inventor
Ramesh S Kashi
Aniket Badkar
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2015001608A1 publication Critical patent/CL2015001608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2015001608A 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. CL2015001608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
CL2015001608A1 true CL2015001608A1 (es) 2015-10-30

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001608A CL2015001608A1 (es) 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Country Status (31)

Country Link
US (3) US20150329632A1 (enExample)
EP (1) EP2931313B1 (enExample)
JP (1) JP6266012B2 (enExample)
KR (1) KR102004585B1 (enExample)
CN (1) CN104870016B (enExample)
AU (1) AU2013359767B2 (enExample)
BR (1) BR112015013540B1 (enExample)
CA (1) CA2894869C (enExample)
CL (1) CL2015001608A1 (enExample)
CY (1) CY1121895T1 (enExample)
DK (1) DK2931313T3 (enExample)
EA (1) EA034616B1 (enExample)
ES (1) ES2732861T3 (enExample)
HR (1) HRP20191137T1 (enExample)
HU (1) HUE045668T2 (enExample)
IL (3) IL307581A (enExample)
LT (1) LT2931313T (enExample)
MX (1) MX357936B (enExample)
MY (1) MY187921A (enExample)
NZ (1) NZ708443A (enExample)
PE (1) PE20151524A1 (enExample)
PH (1) PH12015501296B1 (enExample)
PL (1) PL2931313T3 (enExample)
PT (1) PT2931313T (enExample)
RS (1) RS59057B1 (enExample)
SI (1) SI2931313T1 (enExample)
SM (1) SMT201900414T1 (enExample)
TR (1) TR201909584T4 (enExample)
UA (1) UA117466C2 (enExample)
WO (1) WO2014093203A1 (enExample)
ZA (1) ZA201504408B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
EP3603669B1 (en) * 2017-03-31 2024-06-19 Meiji Seika Pharma Co., Ltd. Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US12036280B2 (en) 2018-11-21 2024-07-16 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
TWI779253B (zh) 2018-11-27 2022-10-01 大陸商信達生物製藥（蘇州）有限公司 抗IL-23p19抗體及其用途
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
AU2020226619A1 (en) * 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
PH12021552536A1 (en) * 2019-04-15 2022-07-04 Sun Pharmaceutical Ind Ltd Methods for treatment of subjects with psoriatic arthritis
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US20210070852A1 (en) * 2019-09-09 2021-03-11 Boehringer Ingelheim International Gmbh Anti-IL-23p19 Antibody Formulations
KR20220143005A (ko) * 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CA3178853A1 (en) * 2020-05-13 2021-11-18 Wei Cao Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3873200A (en) 1999-03-11 2000-09-28 Schering Corporation Mammalian cytokines; related reagents and methods
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
ZA200506159B (en) 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
DK1610820T4 (da) * 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
JP4903061B2 (ja) 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CA2666492C (en) 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
MX2009009079A (es) * 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
AU2008232903B9 (en) * 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102202655B (zh) * 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
MX2011003013A (es) * 2008-09-19 2011-04-11 Pfizer Formulacion liquida estable de anticuerpos.
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
US9220776B2 (en) * 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
SG11201405475UA (en) * 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies

Also Published As

Publication number Publication date
EP2931313A4 (en) 2016-08-03
DK2931313T3 (da) 2019-07-15
CN104870016B (zh) 2018-05-08
MX357936B (es) 2018-07-31
CA2894869C (en) 2021-06-15
PE20151524A1 (es) 2015-11-06
AU2013359767A1 (en) 2015-07-23
MY187921A (en) 2021-10-28
IL239150A0 (en) 2015-07-30
IL307581A (en) 2023-12-01
BR112015013540A2 (pt) 2017-11-14
HUE045668T2 (hu) 2020-01-28
BR112015013540B1 (pt) 2021-04-27
BR112015013540A8 (pt) 2018-04-17
LT2931313T (lt) 2019-09-25
EA034616B1 (ru) 2020-02-27
EA201591133A1 (ru) 2015-10-30
MX2015007213A (es) 2016-08-03
JP6266012B2 (ja) 2018-01-24
IL278295B1 (en) 2023-11-01
CA2894869A1 (en) 2014-06-19
PH12015501296A1 (en) 2015-08-24
TR201909584T4 (tr) 2019-07-22
WO2014093203A1 (en) 2014-06-19
SI2931313T1 (sl) 2019-09-30
JP2016505572A (ja) 2016-02-25
HK1215194A1 (en) 2016-08-19
CN104870016A (zh) 2015-08-26
IL239150B (en) 2020-11-30
EP2931313B1 (en) 2019-05-08
UA117466C2 (uk) 2018-08-10
ZA201504408B (en) 2017-09-27
SMT201900414T1 (it) 2019-09-09
KR20150092763A (ko) 2015-08-13
ES2732861T3 (es) 2019-11-26
US20210188964A1 (en) 2021-06-24
NZ708443A (en) 2018-05-25
EP2931313A1 (en) 2015-10-21
HRP20191137T1 (hr) 2019-09-20
CY1121895T1 (el) 2020-10-14
US20240239884A1 (en) 2024-07-18
RS59057B1 (sr) 2019-08-30
PL2931313T3 (pl) 2019-10-31
PH12015501296B1 (en) 2015-08-24
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
KR102004585B1 (ko) 2019-07-26
IL278295A (enExample) 2020-12-31
AU2013359767B2 (en) 2018-04-05
IL278295B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CL2015001608A1 (es) Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112014032193A2 (pt) métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2015002829A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
BR112013013781A2 (pt) anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
BR112015003938A2 (pt) métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
HRP20190516T1 (hr) Molekula protutijela protiv pd-1 i njihove uporabe
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2015001055A1 (es) Composiciones para lavado de ropa; y uso de dicha composicion.
BR112014005746A2 (pt) tecidos engendrados para usos em pesquisa in vitro, arranjos destes, e métodos de fabricar os mesmos
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112016005594A2 (pt) Uso de ácido poliaspártico modificado, e, composição detergente para lavagem de louça
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
MX2016005956A (es) Anticuerpos especificos para fcrn.
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária